Prognostic Factors for Complete Remission of BLPD After MoAb Therapy
| Risk Factors . | Remission Rate (%)* . | Univariate Analysis (P) . |
|---|---|---|
| Type of transplant | ||
| Marrow | 57 | NS |
| Organ | 64 | |
| Involved sites | ||
| <4 | 82 | ≤.0001 |
| ≥4 | 34 | |
| Clonality† | ||
| Oligo | 80 | ≤.05 |
| Mono | 48 | |
| CNS involvement | ||
| No | 71 | ≤.005 |
| Yes | 29 | |
| BLPD onset‡ | ||
| <365 d | 68 | ≤.01 |
| ≥365 d | 22 | |
| BMT for | ||
| Immunodeficiency | 76 | ≤.01 |
| Hematological malignancies | 27 | |
| Clonality and HM | ||
| Treatment delay2-153 | ||
| <25 d | 68 | NS |
| ≥25 d | 54 | |
| B-cell abnormalities2-155 | ||
| Yes | 63 | NS |
| No | 65 | |
| Antiviral therapy¶ | ||
| Yes | 64 | NS |
| No | 59 | |
| Heavy immunosuppression# | ||
| Yes | 66 | NS |
| No | 54 |
| Risk Factors . | Remission Rate (%)* . | Univariate Analysis (P) . |
|---|---|---|
| Type of transplant | ||
| Marrow | 57 | NS |
| Organ | 64 | |
| Involved sites | ||
| <4 | 82 | ≤.0001 |
| ≥4 | 34 | |
| Clonality† | ||
| Oligo | 80 | ≤.05 |
| Mono | 48 | |
| CNS involvement | ||
| No | 71 | ≤.005 |
| Yes | 29 | |
| BLPD onset‡ | ||
| <365 d | 68 | ≤.01 |
| ≥365 d | 22 | |
| BMT for | ||
| Immunodeficiency | 76 | ≤.01 |
| Hematological malignancies | 27 | |
| Clonality and HM | ||
| Treatment delay2-153 | ||
| <25 d | 68 | NS |
| ≥25 d | 54 | |
| B-cell abnormalities2-155 | ||
| Yes | 63 | NS |
| No | 65 | |
| Antiviral therapy¶ | ||
| Yes | 64 | NS |
| No | 59 | |
| Heavy immunosuppression# | ||
| Yes | 66 | NS |
| No | 54 |
Abbreviation: NS, not significant.
Remission rate as a percentage of the relevant patients.
Clonality data were available for 54 BLPD events.
In days after transplant (d).
Treatment delay in days (d) between first BLPD symptoms and initiation of anti-CD21 and -CD24 therapy.
B-cell abnormalities are defined as the detection of more than 120 B cells/μL or more than 100 plasma cells/μL. Data were available for 45 patients.
¶Antiviral therapy at the time of the anti-CD21 and anti-CD24 therapy with Acyclovir (n = 16), Ganciclovir (n = 8), or Ganciclovir + Foscavir (n = 1).
#Heavy immunosuppression 3 months before BLPD symptoms with ATG, OKT3, or intravenous methylprednisolone at a dose of 5 mg/kg/d for more than 1 week or high-dose methylprednisolone bolus (1 g/1.73 m2).